Bergen, Norway, 16 May 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, is pleased to announce that CEO Martin Olin will be presenting at the ABG Sundal Collier Life Science Summit taking place on Wednesday 18 May at 11:30 CEST. The presentation slides will … Read more
BerGenBio to focus on two key opportunities for its lead compound bemcentinib Strategic focus anchored in strong scientific rationale, supported by dataset from over 600 patients demonstrating bemcentinib’s biological and clinical activity matched with significant unmet medical needs Bergen, Norway,4 May 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors … Read more
Bergen, Norway, 28 April 2022 – Annual general meeting of BerGenBio ASA was virtually held today 28 April 2022 at 10.00 CET. All proposals were resolved as presented in the notice convening the annual general meeting distributed on 7 April 2022, as further set out in the minutes from the annual general meeting attached hereto … Read more
Bergen, Norway, 26 April 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, is pleased to announce that CEO Martin Olin will be presenting at the ArcticSecuritiesBiotech Webinar taking place today at 12:55 CET. The presentation will be made available on the Company’s … Read more
Complete data analysis confirms that the primary endpoint of improved clinical response and key secondary endpoints were met in a subprotocol under the platform ACCORD2 study where bemcentinib was added to standard of care therapy BerGenBio to confirm the ACCORD2 data by progressing bemcentinib into EU-SolidAct, a pan-European platform COVID-19 study enrolling up to 500 … Read more
Bergen, Norway, 25 April 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces that it is presenting data today from its Phase IIa bemcentinib COVID-19 clinical trial (BCBC020) in a poster presentation at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), … Read more
Bergen, Norway, 11 April 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, today announces the appointment of Cristina Oliva, MD as Chief Medical Officer (CMO), effective 25 April 2022. Cristina joins the senior leadership team heading up clinical development of BerGenBio’s selective AXL inhibitor programs. … Read more
Bergen, Norway – 7 April 2022: BerGenBio ASA (OSE:BGBIO) will be holding its Annual General Meeting virtually on 28 April 2022 at 10:00 hours (CEST). The notice, power of attorney and proposal from Nomination Committee are attached to this release. The notice will be sent to all registered shareholders and is available on the Company’s website: … Read more
Bergen, Norway – 7 April 2022- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces that the Board of Directors today approved the 2021 Annual Financial Statements prepared in accordance with International Financial Reporting Standards (IFRS). The Annual Report for 2021 and ESEF file are … Read more
The article identifies the key role of AXL inhibition in restoring response to immune checkpoint blockade therapy in lung cancer with mutations in the STK11/LKB1 gene Bergen, Norway – 17 March 2022- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, today announces the publication of … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.